198 related articles for article (PubMed ID: 23242362)
1. Dopamine dysregulation syndrome in Parkinson's disease patients with unsatisfactory switching from immediate to extended release pramipexole: a further clue to incentive sensitization mechanisms?
Solla P; Cannas A; Corona M; Marrosu MG; Marrosu F
Behav Neurol; 2013 Jan; 27(4):563-6. PubMed ID: 23242362
[TBL] [Abstract][Full Text] [Related]
2. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
O'Sullivan SS; Evans AH; Lees AJ
CNS Drugs; 2009; 23(2):157-70. PubMed ID: 19173374
[TBL] [Abstract][Full Text] [Related]
3. Pramipexole extended release in Parkinson's disease.
Hametner EM; Seppi K; Poewe W
Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
[TBL] [Abstract][Full Text] [Related]
6. Long-term retention rate of pramipexole in the treatment of Parkinson's disease.
Keränen T; Tuhkasaari M; Kuusisto H
Eur J Clin Pharmacol; 2009 Sep; 65(9):955-6; author reply 957. PubMed ID: 19415250
[No Abstract] [Full Text] [Related]
7. Pramipexole extended release: in Parkinson's disease.
Chwieduk CM; Curran MP
CNS Drugs; 2010 Apr; 24(4):327-36. PubMed ID: 20297857
[TBL] [Abstract][Full Text] [Related]
8. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Perez Lloret S; Rascol O
Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease.
Rascol O; Barone P; Hauser RA; Mizuno Y; Poewe W; Schapira AH; Salin L; Sohr M; Debieuvre C;
Mov Disord; 2010 Oct; 25(14):2326-32. PubMed ID: 20669265
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial.
Mizuno Y; Yamamoto M; Kuno S; Hasegawa K; Hattori N; Kagimura T; Sarashina A; Rascol O; Schapira AH; Barone P; Hauser RA; Poewe W;
Clin Neuropharmacol; 2012; 35(4):174-81. PubMed ID: 22801294
[TBL] [Abstract][Full Text] [Related]
11. [Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
Taguchi S; Niwa J; Ibi T; Doyu M
Rinsho Shinkeigaku; 2015; 55(3):182-4. PubMed ID: 25786757
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
Frampton JE
Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
[TBL] [Abstract][Full Text] [Related]
13. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.
Ohno H; Nakajima M; Fujioka S; Iwamoto K; Kawamura M
J Clin Neurosci; 2009 Jun; 16(6):790-2. PubMed ID: 19286385
[TBL] [Abstract][Full Text] [Related]
14. Dopamine agonist induced compulsive eating behaviour in a Parkinson's disease patient.
Khan W; Rana AQ
Pharm World Sci; 2010 Apr; 32(2):114-6. PubMed ID: 20039208
[TBL] [Abstract][Full Text] [Related]
15. Panic attack like episodes possibly associated with pramipexole therapy in Parkinson's disease.
Alonso-Navarro H; Jiménez-Jiménez FJ
Eur J Neurol; 2007 May; 14(5):e1. PubMed ID: 17437590
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
Shen T; Ye R; Zhang B
Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease.
Shen Z; Kong D
Medicine (Baltimore); 2018 Aug; 97(34):e11316. PubMed ID: 30142750
[TBL] [Abstract][Full Text] [Related]
18. Compulsive drumming induced by dopamine agonists in Parkinson's disease: Another aspect of punding.
Vitale C; Trojano L; Barone P; Errico D; Agosti V; Sorrentino G; Grossi D; Santangelo G
Behav Neurol; 2013 Jan; 27(4):559-62. PubMed ID: 23242361
[TBL] [Abstract][Full Text] [Related]
19. Heart valve abnormalities in Parkinson's disease treated with dopamine agonists.
Bares M; Rektorová I; Krajcovicová L; Rektor I
J Neurol; 2008 Oct; 255(10):1596; author reply 1597. PubMed ID: 18758889
[No Abstract] [Full Text] [Related]
20. Pramipexole-induced antecollis in Parkinson's disease.
Suzuki M; Hirai T; Ito Y; Sakamoto T; Oka H; Kurita A; Inoue K
J Neurol Sci; 2008 Jan; 264(1-2):195-7. PubMed ID: 17826796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
